Review of the experience of Neo-adjuvant Chemo Therapy (NACT) practice
Association of Breast Surgery ePoster Library. Muhibullah N. 05/15/17; 166237; P060
Ms. Nazli Muhibullah
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Background: Over the last 10 years NACT has emerged as a first choice of treatment in selected groups with breast cancer. We aim to describe the clinical outcome of patients treated with NACT at our centre; including tumour characteristics, staging, final surgical procedure, disease free (DFS) and overall survival (OS).
Methods: Retrospective review of prospectively maintained NACT database. Review of stage at diagnosis, clinical staging after NACT, final surgical procedure (including breast conservation rates), pCR rates, LRR, DFS and OS. Review of surgical procedure includes breast conservation rates and mastectomy rates.
Results: 335 patients underwent NACT and surgical treatment between 2007 and 2015. Mean age of our cohort 50 years (range 23-80). The mean tumour size at diagnosis of all patients having NACT is 48mm. 37% had T4 disease, 54% node positive, 25% triple negative breast cancer and 26% HER2 positive. After NACT mean tumour size in mastectomy group 23mm (53mm pre-NACT) and BCS 14mm (36mm pre-NACT). Overall pCR in our cohort was 18%, more than half with pCR had a mastectomy, 73% had a measurable response to NACT, 7% had disease progression. 52 had Wide local excision, 29 mammoplasty, 12 partial reconstructions, 214 simple mastectomies and 28 immediate reconstructions. 5 year OS for those having NACT is 79%, DFS 73%.
Conclusions: There is increasing uptake of NACT in our population with increasing rates of more complex surgery after NACT. Overall 5 year survival rates are approaching 80% at 5 years with disease free survival 73%.
Methods: Retrospective review of prospectively maintained NACT database. Review of stage at diagnosis, clinical staging after NACT, final surgical procedure (including breast conservation rates), pCR rates, LRR, DFS and OS. Review of surgical procedure includes breast conservation rates and mastectomy rates.
Results: 335 patients underwent NACT and surgical treatment between 2007 and 2015. Mean age of our cohort 50 years (range 23-80). The mean tumour size at diagnosis of all patients having NACT is 48mm. 37% had T4 disease, 54% node positive, 25% triple negative breast cancer and 26% HER2 positive. After NACT mean tumour size in mastectomy group 23mm (53mm pre-NACT) and BCS 14mm (36mm pre-NACT). Overall pCR in our cohort was 18%, more than half with pCR had a mastectomy, 73% had a measurable response to NACT, 7% had disease progression. 52 had Wide local excision, 29 mammoplasty, 12 partial reconstructions, 214 simple mastectomies and 28 immediate reconstructions. 5 year OS for those having NACT is 79%, DFS 73%.
Conclusions: There is increasing uptake of NACT in our population with increasing rates of more complex surgery after NACT. Overall 5 year survival rates are approaching 80% at 5 years with disease free survival 73%.
Background: Over the last 10 years NACT has emerged as a first choice of treatment in selected groups with breast cancer. We aim to describe the clinical outcome of patients treated with NACT at our centre; including tumour characteristics, staging, final surgical procedure, disease free (DFS) and overall survival (OS).
Methods: Retrospective review of prospectively maintained NACT database. Review of stage at diagnosis, clinical staging after NACT, final surgical procedure (including breast conservation rates), pCR rates, LRR, DFS and OS. Review of surgical procedure includes breast conservation rates and mastectomy rates.
Results: 335 patients underwent NACT and surgical treatment between 2007 and 2015. Mean age of our cohort 50 years (range 23-80). The mean tumour size at diagnosis of all patients having NACT is 48mm. 37% had T4 disease, 54% node positive, 25% triple negative breast cancer and 26% HER2 positive. After NACT mean tumour size in mastectomy group 23mm (53mm pre-NACT) and BCS 14mm (36mm pre-NACT). Overall pCR in our cohort was 18%, more than half with pCR had a mastectomy, 73% had a measurable response to NACT, 7% had disease progression. 52 had Wide local excision, 29 mammoplasty, 12 partial reconstructions, 214 simple mastectomies and 28 immediate reconstructions. 5 year OS for those having NACT is 79%, DFS 73%.
Conclusions: There is increasing uptake of NACT in our population with increasing rates of more complex surgery after NACT. Overall 5 year survival rates are approaching 80% at 5 years with disease free survival 73%.
Methods: Retrospective review of prospectively maintained NACT database. Review of stage at diagnosis, clinical staging after NACT, final surgical procedure (including breast conservation rates), pCR rates, LRR, DFS and OS. Review of surgical procedure includes breast conservation rates and mastectomy rates.
Results: 335 patients underwent NACT and surgical treatment between 2007 and 2015. Mean age of our cohort 50 years (range 23-80). The mean tumour size at diagnosis of all patients having NACT is 48mm. 37% had T4 disease, 54% node positive, 25% triple negative breast cancer and 26% HER2 positive. After NACT mean tumour size in mastectomy group 23mm (53mm pre-NACT) and BCS 14mm (36mm pre-NACT). Overall pCR in our cohort was 18%, more than half with pCR had a mastectomy, 73% had a measurable response to NACT, 7% had disease progression. 52 had Wide local excision, 29 mammoplasty, 12 partial reconstructions, 214 simple mastectomies and 28 immediate reconstructions. 5 year OS for those having NACT is 79%, DFS 73%.
Conclusions: There is increasing uptake of NACT in our population with increasing rates of more complex surgery after NACT. Overall 5 year survival rates are approaching 80% at 5 years with disease free survival 73%.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}